Article

Emerging Therapies in Acute Migraine Treatment

Neurology Reviews. 2011 July;19(7):27

References

Suggested Reading
Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51(4):507-517.
Djupesland PG, Docekal P. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. Cephalalgia. 2010;30(8):933-942.
Ferrari MD, Färkkilä M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan—a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170-1178.
Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol. 2011;13(1):1-14.
Pierce M, Marbury T, O’Neill C, et al. Zelrix: a novel transdermal formulation of sumatriptan. Headache. 2009;49(6):817-825.
Storer RJ, Immke DC, Goadsby PJ. Large conductance calcium-activated potassium channels (BKCa) modulate trigeminovascular nociceptive transmission. Cephalalgia. 2009;29(12):1242-1258.

Emerging Therapies in Acute Migraine Treatment

References

Pages

Recommended Reading